

Efficacy of exosomes in acute kidney injury treatment and the associated mechanism (Review)

ZEHAO ZHANG, LECHENG SHE and MING BAI

Department of Nephrology, Xijing Hospital, The Fourth Military Medical University, Xi'an, Shaanxi 710032, P.R. China

Received November 23, 2024; Accepted January 31, 2025

DOI: 10.3892/mmr.2025.13503

Abstract. Acute kidney injury (AKI) is a syndrome characterized by rapid loss of renal function with a high morbidity and mortality. However, due to the complex pathophysiologic mechanisms of AKI, no specific treatment for this disease is currently available. Animal models have demonstrated the protective effects of exosomes on AKI; however, the underlying mechanisms require further investigation. The present review focuses on the efficacy of exosomes derived from different cell sources, including mesenchymal stem cells, endothelial progenitor cells and tubular epithelial cells, in the treatment of AKI and the associated mechanism. Furthermore, the effects of exosomal contents, including microRNAs, circular RNAs, long non-coding RNAs, messenger RNAs and proteins, on the repair of renal tubules, protection against renal tubular epithelial cell injury, protection against fibrosis, inhibition of early endoplasmic reticulum stress and mediation of inflammation during AKI are also summarized in the present review.

Contents

1. Introduction
2. Therapeutic effect of exosomes on AKI
3. Novel advances in exosome therapy
4. Conclusion

Correspondence to: Professor Ming Bai, Department of Nephrology, Xijing Hospital, The Fourth Military Medical University, 127 Changle West Road, Xi'an, Shaanxi 710032, P.R. China
E-mail: mingbai1983@126.com

Abbreviations: AKI, acute kidney injury; S-AKI, sepsis-induced AKI; Cis-AKI, cisplatin-induced AKI; V-AKI, vancomycin-induced AKI; I/R-AKI, ischemia-reperfusion-induced AKI; ROS, reactive oxygen species; EV, extracellular vesicle; MSC, mesenchymal stem cell; huMSC, human umbilical cord-derived MSC; hAEC, human amniotic epithelial cell; TEC, renal tubular epithelial cell; rIPC, remote ischemic preconditioning; NEXs, neutrophil cell membrane-engineered huMSC-secreted EVs

Key words: exosomes, AKI, MSC, macrophage

1. Introduction

Acute kidney injury (AKI) involves rapid deterioration of kidney function, typically occurring over a period of hours to days, and is defined by an increase in serum creatinine levels, a decrease in urine output or both. AKI occurs in 10-15% of hospitalized patients and >50% of patients in intensive care units. Since AKI is a highly heterogeneous disease, its complex pathophysiological mechanisms are not completely understood (1). Currently, no effective treatment or prevention method is available for AKI (1,2). AKI can be caused by several drugs and toxins, such as cisplatin-induced AKI (Cis-AKI) and vancomycin-induced AKI (V-AKI). In addition, sepsis-induced AKI (S-AKI) and ischemia-reperfusion (I/R)-induced AKI (I/R-AKI) are also commonly reported (3-5). The main pathogenic mechanisms of AKI are oxidative stress and cytotoxicity caused by the accumulation of reactive oxygen species (ROS) and toxins due to dysfunction of enzyme-promoted and non-enzyme-promoted antioxidant defense systems, resulting in renal tissue damage and renal dysfunction (6-9).

Extracellular vesicles (EVs) are a heterogeneous group of membrane-bound vesicles and EVs can be divided into micro-vesicles, exosomes and apoptotic bodies according to their size, biological processes and molecular markers (10). Exosomes are an important type of EV, with a size of 40-200 nm and an average diameter of 100 nm (10,11). Exosomes originate from endosomes and are secreted and released by a variety of cells, including mesenchymal stem cells (MSCs) and neutrophils (11). Increasing evidence suggests that exosomes serve an important role in intercellular communication, and the pathways related to exosome uptake include receptor-ligand binding, membrane fusion and endocytosis (10-13). For example, proteins, microRNAs (miRNAs/miRs), circular RNAs, lipids, DNA and long non-coding RNAs (lncRNAs) are delivered to target cells to regulate cell functions (10-15). Although the potential mechanisms underlying the targeted regulation of exosomes are diverse and complex, several studies have revealed the regulatory role of exosome-supported biomolecules in renal I/R injury (12,16,17). However, further investigation of the effects of exosomes on AKI progression is necessary. Exosomes secreted by cells and substances from different sources differ in terms of their efficacy and mechanism of action on AKI, which are discussed and summarized in the present review.

2. Therapeutic effect of exosomes on AKI

Effects of exosomes derived from MSCs on AKI. Previous studies have revealed that MSCs have the capacity for self-renewal, differentiation, immune regulation and nutritional support, and are essential in regenerative medicine because of their ability to create a microenvironment conducive to the repair of damaged tissues (17,18). Previously, a phase Ia clinical trial demonstrated that MSCs can increase renal blood flow and the glomerular filtration rate, and reduce inflammation in the kidneys after stenosis (18-20). The therapeutic effect of MSCs is generally considered to be mediated by the secretion of various factors, including cytokines, cell growth factors and exosomes (21). Exosome-rich components are recognized as key active therapeutic ingredients for MSC-based therapies. Compared with adult stem cell therapy, exosome therapy has certain advantages, including increased consistency, enhanced potency, greater scalability of manufacturing and a wide range of sources (22,23). MSCs can be isolated from a variety of tissues, including the bone marrow, fat, umbilical cord and placenta, and extracted from substances such as dental pulp, skin, blood and urine (10,24,25).

Exosomes from different types of MSCs can promote tubular repair, alleviate tubular epithelial cell damage, inhibit inflammation, oxidative stress and apoptosis, and alleviate renal I/R injury (14,18,26-30). Previous studies have shown that the transfusion of human umbilical cord-derived MSC (huMSC) exosomal miR-874-3p into a mouse model of Cis-AKI and transfection into Cis-HK-2 reduced the activation of necroptosis, and promoted mitochondrial homeostasis and the repair of tubular epithelial cell injury by targeting the receptor-interacting serine/threonine protein kinase 1 (RIPK1)/PGAM5 pathway (27,29). Adipose-derived stem cell-derived exosomal CIRCUMA21 and miR-342-5p alleviated lipopolysaccharide (LPS)-stimulated HK-2 cell damage, inhibited oxidative stress and inflammation, increased renal function, and restored normal tissue morphology by targeting miR-16-5p and inhibiting toll-like receptor 9 (3,31). In addition, physiological homeostasis of the plasma metabolome could be maintained in a male cat model of postrenal AKI, effectively improving renal function of the cats (3,25,28,31,32). Furthermore, the exosomes miR-199a-3p and miR-199a-5p from bone marrow mesenchymal stem cells also have effects on AKI. First, miR-199a-3p inhibits apoptosis and inflammation in I/R mouse models by activating the AKT/ERK pathway. Secondly, miR-199a-5p targeted immunoglobulin protein, inhibited apoptosis and alleviated endoplasmic reticulum stress in I/R mouse models (12,14).

In addition, human urine-derived stem cell (hUSC) exosomes carrying miR-146a-5p and miR-216a-5p also play a role. First, miR-146a-5p inhibits inflammation and apoptosis and promotes renal tubular cell proliferation by targeting interleukin-1 receptor-associated kinase-1. Second, miR-216a-5p targets the PTEN/Akt signaling pathway, inhibits inflammation and oxidative stress, and reduces I/R-AKI in mice (33,34). Furthermore, klotho, a reno-protective protein expressed by hUSCs, migrates to the site of kidney injury and carries out a protective role through a similar mechanism (35). In addition, ferroptosis is a unique mode of cell death induced by iron-mediated lipid peroxidation accumulation and plasma

membrane rupture. Exosomes derived from hUSCs carry the lncRNA taurine upregulated 1 and regulate achaete-scute homolog 4-mediated iron death by interacting with serine/arginine-rich splicing factor 1 to inhibit tubular cell epithelial cell damage and alleviate kidney injury (36,37). Iron overload promotes M1 macrophage activation and subsequent inflammation (38). Therefore, future work should combine anti-ferroptosis and anti-inflammatory therapy to potentially increase the therapeutic efficacy of the treatment for inflammation. In combination with immunization and other methods, the application of MSC-exosome-mediated ferroptosis in the treatment of various diseases is expected to increase (36,38-41). Future studies may explore whether exosomes serve roles in other forms of cell death, such as copper-induced cell death, in the occurrence and development of disease (42).

Although studies have shown that exosomes derived from MSCs serve a positive role in the development of AKI (3,12,14,27,31,33,34,43), evidence from animal model studies is limited. This is partly because of ethical constraints; thus, the participation of regulatory bodies, such as ethical review committees, in exosome research is key. In addition, due to the shortcomings of MSCs, such as insufficient clinical validation, unstable sources and quality, and the complex physiological structure and mechanism of the human body, when MSCs are used as drugs, it is necessary to consider whether resistance or immune reactions may occur in the process, which may prevent initial therapeutic effects and exacerbate damage (10,40,41,44) (Fig. 1; Table I).

Efficacy of exosomes derived from other cells in AKI treatment and the associated mechanisms. In addition to MSCs, exosomes secreted by other cells and substances have therapeutic effects on AKI. Exosomes from the urine of premature infants were effective against Cis-AKI (45). Exosomal miR-30a-5p serves a role by activating MAPK8. It reduces the expression of cisplatin-induced cleaved caspase-3, monocyte chemoattractant protein-1 (MCP-1) and Bax, and increases Bcl-2 expression (45). Therefore, miR-30a-5p inhibits cell inflammation and apoptosis, and serves a protective role in the kidney. In V-AKI, human urinary exosomes may serve as biomarkers for drug-induced kidney injury, and exhibit potential as biomarkers, targets and therapeutics for immunomodulatory compounds (45,46).

Exosomal miR-486-5p from endothelial colony-forming cells is effective against I/R-AKI. Exosomal miR-486-5p serves an important role by targeting the PTEN/Akt pathway to alleviate renal tubular epithelial cell (TEC) inflammation and inhibit fibrosis (47,48). In mouse models of CLP, endothelial progenitor cell-derived exosomal miR-21-5p improved kidney function by inhibiting runt-related transcription factor 1 expression, apoptosis and inflammatory responses (49).

Human amniotic epithelial cells (hAECs) are non-MSCs that are isolated from the placental amniotic epithelial membrane. hAECs respond to immunomodulatory therapy, express anti-inflammatory proteins, including IL-10 and IL-12, and have the advantages of abundant sources, large quantities and genetic stability (50). In mice subjected to cecal ligation and puncture, hAEC-derived exosomes inhibited vascular cell adhesion factor 1 through immunomodulation, thereby controlling cellular inflammation and reducing fluorescein




Figure 1. Exosomal contents of mesenchymal stem cells, such as proteins, lncRNAs and miRNAs, inhibit AKI-induced inflammation and apoptosis, and promote the proliferation of renal tubular epithelial cells by regulating various proteins involved in AKI or acting on certain pathways. ADMSC, adipose-derived mesenchymal stem cell; AKI, acute kidney injury; BIP, binding immunoglobulin protein; BMSC, bone marrow mesenchymal stem cell; Cis, cisplatin; Cis-AKI, Cis-induced AKI; CLP, cecal ligation and puncture; H/R, hypoxia/reoxygenation; huMSC, human umbilical cord-derived mesenchymal stem cell; I/R, ischemia-reperfusion; IRAK1, interleukin-1 receptor-associated kinase 1; lncRNA, long non-coding RNA; LPS, lipopolysaccharide; miR/miRNA, microRNA; RIPK1, receptor-interacting serine/threonine protein kinase 1; SRSF1, serine and arginine rich splicing factor 1; TLR9, toll-like receptor 9; hUSCs, human urine-derived stem cells.

isothiocyanate-dextran leakage. Therefore, the integrity of the endothelial monolayer and glomerular endothelial cells was protected, and the functional damage to endothelial cells induced by s-AKI was alleviated (51,52).

TECs are typically the site of injury caused by hypoxia, inflammation and toxins, and TEC injury serves a role in promoting disease progression. miR-19b-3p in exosomes from TECs activate the NF- κ B signaling pathway in macrophages by targeting suppressor of cytokine-signaling-1. Increased p65 and phosphorylated-p65 protein levels increase the expression levels of MCP-1 and TNF- α , regulate the activation mechanism of M1 macrophages and promote the progression of renal tubulointerstitial inflammation facilitated by macrophages. Exosomal miR-19b-3p levels are positively associated with the severity of proteinuria (53-55). This finding is the opposite of the protective effect of mesenchymal stem cell exosomes on the kidneys reported in previous studies (33,53), and it is hypothesized that the inflammatory response in AKI may be caused by the exosome-mediated inflammatory pathway through the promotion of TEC macrophage activation. Therefore, miR-16b-3p is a potential target for the treatment of AKI (53,54).

The study also revealed that exosomes from the plasma of patients undergoing heart surgery were effective in mouse models of I/R. Exosomal miR-590-3p reduced I/R-induced oxidative stress by targeting RIPK1. Furthermore, LC3 II and Beclin-1 protein expression levels were decreased, p62 protein expression was increased, and TNF receptor-associated

factor 6 could be targeted to regulate autophagy and alleviate LPS-induced AKI and podocyte apoptosis, which had a protective effect on the kidneys (55).

The therapeutic effect of cellular exosomes on S-AKI has also been investigated. Remote ischemic preconditioning (rIPC) also has a protective effect. rIPC is a beneficial stimulator triggered by transient I/R in remote tissues (2). Previous studies have revealed that rIPC has a beneficial effect on a variety of organs (56-59). After rIPC, the kidney promotes the expression of miR-21, which inhibits PTEN expression and NF- κ B activity. Therefore, inhibition of HIF-1 α abrogates renoprotection induced by rIPC in mice (2,56) (Fig. 2; Table II).

3. Novel advances in exosome therapy

Engineering exosomes. Several studies have shown that MSCs and other cell- and substance-derived exosomes have positive roles in the treatment and prevention of AKI (3,31,33,34,53,55,57). However, these exosomes are deficient in the treatment of AKI, and their therapeutic effects are limited. At present, no standard system exists for the mass production, separation and storage of exosomes. Therefore, the engineering of exosomes is necessary. This process can enhance the targeting of injured sites and treatment specificity or improve resistance to body clearance. The engineering of exosomes involves the modification of natural exosomes using biological and chemical engineering techniques, and

Table I. Role of the exosomal contents of MSCs in AKI.

First author/s, year	Exosome source	Model	Effect	Pathways	Contents	(Refs.)
Yu <i>et al</i> , 2023	huMSC	UUO mice; Cis HK-2 cells; Cis-NRK-52E cells; Cis-AKI mice	Anti-inflammation; anti-apoptotic; reduces oxidative stress	Targeting RIPK1/PGAM5	miR-874-3p	(27)
He <i>et al</i> , 2023	ADMSC	LPS-AKI mice; LPS-HK-2 cells	Anti-inflammation; anti-apoptotic; reduces oxidative stress; reduces cell damage	Targeting miR-16-5P	CIRCUMA21	(3)
Liu <i>et al</i> , 2023	ADMSC	LPS HK-2 cells; CLP mice	Anti-inflammation; anti-apoptotic; promotes autophagy; inhibits endoplasmic reticulum stress; maintains endothelial integrity	Inhibiting TLR9	miR-342-5p	(31)
Zhang <i>et al</i> , 2020	hUSC	H/R HK-2 cells; I/R mice	Anti-inflammation; anti-apoptotic; promotes the proliferation of HK-2 cells	Regulating the miR-216a-5p/PTEN/Akt signaling pathway	miR-216a-5p	(34)
Li <i>et al</i> , 2020	hUSC	IRI mice; H/R HK-2 cells	Anti-inflammation; anti-apoptotic; anti-oxidative	Targeting the 3'UTR of IRAK1 mRNA and inhibiting the activation NF- κ B signaling	miR-146a-5p	(33)
Sun <i>et al</i> , 2022	hUSC	IRI mice; H/R HK-2 cells	Reduces the level of ROS; ameliorates ferroptosis; alleviates cell apoptosis	Interacting with SRSF1 to regulate ASCL4-mediated ferroptosis	lncRNA TUG1	(36)
Zhu <i>et al</i> , 2019	BMSC	H/R HK-2 cells; I/R mice	Anti-apoptotic; anti-inflammation	Downregulating Sema3A expression and thereby activating the AKT and ERK pathways	miR-199a-3p	(14)
Wang <i>et al</i> , 2019	BMSC	I/R rats; H/R NRK-52E cells	Anti-apoptotic; inhibits ER stress; reduces tubular necrosis	Targeting binding immunoglobulin protein	miR-199a-5p	(12)

3'UTR, 3' untranslated region; ADMSC, adipose-derived MSC; AKI, acute kidney injury; ASCL4, achaete-scute family bHLH transcription factor 4; BMSC, bone marrow MSC; Cis, cisplatin; Cis-AKI, Cis-induced AKI; CLP, cecal ligation and puncture; ER, endoplasmic reticulum; H/R, hypoxia/reoxygenation; huMSC, human umbilical cord-derived MSC; hUSC, human urine-derived stem cell; I/R, ischemia-reperfusion; IRAK1, interleukin-1 receptor associated kinase 1; IRI, ischemia reperfusion injury; lncRNA, long non-coding RNA; LPS, lipopolysaccharide; miR, microRNA; MSC, mesenchymal stem cell; RIPK1, receptor-interacting serine/threonine protein kinase 1; ROS, reactive oxygen species; Sema3A, semaphorin 3A; SRSF1, serine and arginine rich splicing factor 1; TLR9, toll-like receptor 9; UUO, unilateral ureteral obstruction.




Figure 2. Exosomal contents from other cells and substances act on damaged kidney tissue, have anti-inflammatory and anti-apoptotic effects, and can promote vascular regeneration and inhibit fibrosis, thereby protecting the kidney. By contrast, exosomal content from TEC promotes macrophage activation, and thus, mediates inflammatory responses, a role opposite to that of other exosomes. ADR, adriamycin; Cis, cisplatin; CLP, cecal ligation and puncture; ECFC, endothelial colony-forming cell; EPC, endothelial progenitor cell; H/R, hypoxia/reoxygenation; I/R, ischemia-reperfusion; LPS, lipopolysaccharide; miR, microRNA; mTEC, mice tubular epithelial cells; PDCD4, programmed cell death 4; rIPC, remote ischemic preconditioning; RUNX1, runt-related transcription factor 1; SOCS-1, suppressor of cytokine signaling 1; TEC, renal tubular epithelial cell; TRAF6, TNF receptor associated factor 6.

the modification of endogenous and exogenous loads through bioengineering refers to the introduction of targeting motifs by genetically fusing membrane-bound proteins (60-62). Chemical engineering refers to the addition of substances such as antibodies, proteins and small molecules through lipid chemical reactions, membrane-bound protein chemical reactions or lipid-lipid interactions, amplifying the advantages and specific functions of various nano-delivery systems (55,60). To date, engineered exosomes have been studied for the treatment of a variety of diseases, such as Cis-AKI. huMSC-derived exosomes exhibit a low targeting ability and therapeutic specificity for tissue damage repair. Therefore, neutrophil cell membrane-engineered huMSC-sEVs (NEXs) have been developed to enhance the specificity of targeting huMSC-sEVs. NEXs effectively target the site of kidney injury, considerably reduce ROS levels, and strengthen anti-inflammatory, antioxidative stress and antiapoptotic effects (43). Exosome engineering provides a more accurate and personalized treatment outlook for AKI (10,43,62,63).

Smart nano-exosomes. Smart nano-exosomes are nano-cellular double vesicles that are present in the endosomal region of the majority of eukaryotes and the cytoplasm of several types of bacteria (64). Smart nano-exosomes are formed when multivesicular bodies are secreted together with fused plasma membranes through the exocytosis of intracellular vesicles (65). Nanomaterials with considerable pharmacokinetic, bioavailability and biodistribution properties, such as low toxicity and immunogenicity, penetrate other

cells without being targeted by the immune system or toxic reactions, and enable more efficient penetration and delivery of cargoes carrying molecules (66). Thus, these materials have the potential to further elucidate complex biological responses, and represent a promising tool for the diagnosis and treatment of multiple diseases (64-66). Currently, nanoscale single-cell gene manipulation is an effective method to screen for intelligent exosomes that can be directly modified by stem cell modification to increase the 'intelligent' properties of exosomes (67-69). Nano-exosomes have been investigated for the treatment of viral diseases, cancer and cardiovascular diseases (70,71), but there is a gap in AKI research. Previous studies have shown that intelligent nano-exosomes are a rich source of potential biomarkers, and that their secretion into extracellular regions provides convenient conditions for the examination of body fluids such as urine and blood (72,73). Therefore, studies should explore whether they can be used as novel biomarkers for the diagnosis of AKI (68-73).

Applications of nanotechnology in AKI. Gene therapy and stem cell therapy use can improve the effectiveness of AKI treatment, but early use of stem cell therapy for AKI treatment requires research to confirm its long-term safety and assess the risk of developing fibrosis (74). Therefore, due to the rapid development of nanotechnology, nanotechnology has been used to develop early and accurate diagnostic methods and effective treatments for various kidney diseases (75). Modified TiO₂ nanotube arrays, nanosensor, nanotubes, nanorod, nanospheres and iron oxide nanoparticles have been developed, enabling

Table II. Role of the exosome contents of other cells and substance origin in AKI.

First author/s, year	Exosome source	Model	Effects	Pathways	Contents	(Refs.)
Zhang <i>et al</i> , 2021	EPCs	CLP mice	Anti-apoptotic; anti-inflammation; reduces oxidative stress	Inhibiting RUNX1 expression	miR-21-5p	(49)
Vinas <i>et al</i> , 2016	ECFCs	I/R mice; H/R ECFC cells	Anti-inflammation; inhibits fibrosis	Targeting PTEN and the Akt pathway	miR-486-5p	(47)
Lv <i>et al</i> , 2020	TEC	LPS mice; ADR mice	Promotes M1 macrophage activation; promotes inflammation	Leading to M1 phenotype polarization by targeting NF- κ B/SOCS-1	miR-19b-3p	(53)
Ma <i>et al</i> , 2022	Urine	Cis-AKI mice; Cis HK-2 cells	Promotes cell regeneration; anti-apoptotic; anti-inflammation	Targeting and downregulating MAPK8	miR-30a-5p	(45)
Chen <i>et al</i> , 2022	Plasma	H/R HK-2 cells	Anti-apoptotic; reduces oxidative stress; promotes autophagy	Targeting TRAF6	miR-590-3p	(55)
Pan <i>et al</i> , 2019	rIPC	Limb rIPC; CLP mice; LPS mTEC cells	Anti-inflammation; anti-apoptotic	Targeting the downstream PDCD4/NF- κ B and PTEN/AKT pathways	miR-21	(2)

ADR, adriamycin; AKI, acute kidney injury; Cis, cisplatin; Cis-AKI, Cis-induced AKI; CLP, cecal ligation and puncture; ECFC, endothelial colony-forming cell; EPC, endothelial progenitor cell; H/R, hypoxia/reoxygenation; I/R, ischemia-reperfusion; LPS, lipopolysaccharide; miR, microRNA; mTEC, mouse tubular epithelial cells; PDCD4, programmed cell death 4; rIPC, remote ischemic preconditioning; RUNX1, runt-related transcription factor 1; SOCS-1, suppressor of cytokine signaling 1; TEC, renal tubular epithelial cell; TRAF6, TNF receptor associated factor 6.




Figure 3. Nanodrug delivery systems can accurately deliver drugs to the damaged site of the kidney, which can inhibit inflammation and apoptosis. In addition, it can inhibit oxidative stress of endoplasmic reticulum, repair damaged kidney tissue, and monitor the physical condition of patients at an early stage. AKI, acute kidney injury.

researchers to sensitively, accurately and conveniently diagnose and continuously monitor the status of patients with AKI using methods such as biomarker monitoring, ultrasound detection and optical imaging (76). In addition, various delivery systems, including polymer nanoparticles, organic nanoparticles, inorganic nanoparticles, lipid nanoparticles and hydrogels, are currently available (74-76). Polymer nanoparticles can be modified with a variety of components that precisely control the characteristics of the nanoparticles, increasing the targeting ability and anti-inflammatory and antioxidant effects of the delivered exosomes (74,77). Inorganic nanoparticles, which can effectively clear ROS, provide a novel option for the treatment of various diseases caused by oxidative stress (78,79). Lipid nanoparticles use biocompatible and physiologically tolerated lipids to improve the solubility of hydrophobic drugs and enhance biocompatibility, making it easier for loaded drugs or exosomes to reach damaged sites, improving therapeutic efficacy and reducing systemic side effects (80,81).

In addition, hydrogels are also the focus of current research. Hydrogels are hydrophilic gels with 3D network structures composed of soft, biocompatible and biodegradable materials. Due to their advantages of high biocompatibility, injection flexibility and controllability, hydrogels can be easily injected (82,83). For example, hydrogels loaded with osteoinductive dental pulp stem cell-derived EVs enhance bone tissue remodeling and adhesion, and promote bone growth (82). The use of hydrogels as delivery systems has also been applied to the treatment of AKI. Studies have shown that the delivery of MSC-EVs to the injured site through hydrogels can increase the bioavailability of MSC-EVs, effectively alleviate the induced inflammatory response and reduce the remodeling of the extracellular matrix, which is expected to become an

innovative treatment method for AKI (74,83-85). Finally, nano-carriers can assist in the delivery of small interfering RNAs between cells, increase their plasma stability and targeting, prolong their circulation time, and modulate their pharmacokinetics (86). Studies have prepared megalin-targeting polycationic polymyxin-polyethylenimine/DNA-nanoplexes for kidney-targeted gene delivery to improve gene transfection efficiency. This opens novel avenues for kidney gene therapy for AKI (68,87,88) (Fig. 3; Table III).

4. Conclusion

The present review summarizes the role and mechanism of exosomes derived from different cells and substances in AKI. Exosomes serve an important role in the occurrence and development of AKI by regulating certain pathways or targeting specific sites. For example, the exosome miR-874-3p from huMSC targets RIPK1/PGAM5 to inhibit inflammation and apoptosis. In addition, the exosome miR-216a-5p derived from hUSCs promotes the proliferation of HK-2 cells by targeting the PTEN/Akt signaling pathway. The therapeutic effects of exosomes from different sources on different pathological characteristics of AKI are also discussed by examining their reparative effects on renal tubule injury, and anti-inflammatory and anti-apoptotic effects. The roles of certain exosomes in promoting AKI are also discussed. For instance, the exosome miR-19b-3p derived from TEC can promote the activation of M1 macrophages and promote inflammation, thus promoting the development of AKI. Furthermore, future trends in the development of exosome therapy and some possible challenges, including ethical issues and unclear mechanisms of exosome action on damaged sites, are also discussed. Finally,

Table III. Role of engineered exosomes and nanotechnology in AKI.

First author/s, year	Exosome source	Model	Effects	Pathways	Contents	(Refs.)
Wu <i>et al</i> , 2022	NEX	Cis-AKI mice; Cis-NRK52E cells	Promotes cell proliferation; reduces the levels of ROS	NEX enhances the targeting of huMSC-sEVs	Engineered exosomes	(43)
Latifkar A <i>et al</i> , 2019	Nanotechnology	Mice; cells	Anti-inflammation; reduces oxidative stress; Monitor the status of patients with AKI	Enhance the targeting and specificity of exosomes	Polymer nanoparticles; hydrogels; smart nanoeosomes	(67,74-76)
Zhao <i>et al</i> , 2021						
Sun <i>et al</i> , 2019						
Mi <i>et al</i> , 2016						

AKI, acute kidney injury; Cis, cisplatin; Cis-AKI, Cis-induced AKI; huMSC-sEVs, human umbilical cord mesenchymal stem cells-derived small extracellular vesicles; NEX, neutrophil cell membrane-engineered huMSC-sEVs; ROS, reactive oxygen species.

the present review discusses the current development trends of exosome therapy and reveals that there are still several issues that remain to be solved. For instance, the field of engineering exosomes, nano-exosomes and gene-edited exosomes still needs to be explored, and the utilization of nanotechnology in these domains remains relatively rare. Unique therapeutic cargoes with biological and clinical therapeutic effects may be loaded into exosomes derived from various cells and substances, and further exploration of the pathogenesis of AKI and the mechanism of action of exosomes is needed. Subsequently, exosome therapy may provide more possibilities in regenerative medicine and the treatment of some diseases, and provides novel options with potential for the treatment of AKI.

Acknowledgements

Not applicable.

Funding

The present study was supported by the National Natural Science Foundation of China (grant no. 82070699), the Project of Medical Staff Technical Elevation of the Xijing Hospital of the Fourth Military Medical University (grant no. 2023XJSZ06) and the Discipline Promotion Project of the Xijing Hospital of the Fourth Military Medical University (grant no. XJZT24LY26).

Availability of data and materials

Not applicable.

Authors' contributions

ZZ and MB conceived the present study and revised the manuscript. ZZ and MB wrote and revised the manuscript, and constructed and revised the figures. LS revised the manuscript. All authors have read and approved the final manuscript. Data authentication is not applicable.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

- Scholz H, Boivin FJ, Schmidt-Ott KM, Bachmann S, Eckardt KU, Scholl UI and Persson PB: Kidney physiology and susceptibility to acute kidney injury: Implications for renoprotection. *Nat Rev Nephrol* 17: 335-349, 2021.
- Pan T, Jia P, Chen N, Fang Y, Liang Y, Guo M and Ding X: Delayed Remote ischemic preconditioning confers renoprotection against septic acute kidney injury via exosomal miR-21. *Theranostics* 9: 405-423, 2019.

3. He Y, Li X, Huang B, Yang Y, Luo N, Song W and Huang B: Exosomal circvma21 derived from Adipose-derived stem cells alleviates Sepsis-induced acute kidney injury by targeting Mir-16-5p. *Shock* 60: 419-426, 2023.
4. Jorgensen SCJ, Murray KP, Lagnf AM, Melvin S, Bhatia S, Shamim MD, Smith JR, Brade KD, Simon SP, Nagel J, *et al*: A multicenter evaluation of Vancomycin-associated acute kidney injury in hospitalized patients with acute bacterial skin and skin structure infections. *Infect Dis Ther* 9: 89-106, 2020.
5. Fathy N, Farouk S, Sayed RH and Fahim AT: Ezetimibe ameliorates cisplatin-induced nephrotoxicity: A novel therapeutic approach via modulating AMPK/Nrf2/TXNIP signaling. *FASEB J* 38: e23382, 2024.
6. Li Y, Hu C, Zhai P, Zhang J, Jiang J, Suo J, Hu B, Wang J, Weng X, Zhou X, *et al*: Fibroblastic reticular cell-derived exosomes are a promising therapeutic approach for septic acute kidney injury. *Kidney Int* 105: 508-523, 2024.
7. Huang TY, Chien MS and Su WT: Therapeutic potential of pretreatment with exosomes derived from stem cells from the apical papilla against Cisplatin-induced acute kidney injury. *Int J Mol Sci* 23: 5721, 2022.
8. Guo G, Wang Y, Kou W and Gan H: Identifying the molecular mechanisms of sepsis-associated acute kidney injury and predicting potential drugs. *Front Genet* 13: 1062293, 2022.
9. Chen L, Xu JY and Tan HB: LncRNA TUG1 regulates the development of ischemia-reperfusion mediated acute kidney injury through miR-494-3p/E-cadherin axis. *J Inflamm (Lond)* 18: 12, 2021.
10. Zhang X, Wang J, Zhang J, Tan Y, Li Y and Peng Z: Exosomes highlight future directions in the treatment of acute kidney injury. *Int J Mol Sci* 24: 15568, 2023.
11. Jiao Y, Zhang T, Zhang C, Ji H, Tong X, Xia R, Wang W, Ma Z and Shi X: Exosomal miR-30d-5p of neutrophils induces M1 macrophage polarization and primes macrophage pyroptosis in sepsis-related acute lung injury. *Crit Care* 25: 356, 2021.
12. Wang C, Zhu G, He W, Yin H, Lin F, Gou X and Li X: BMSCs protect against renal ischemia-reperfusion injury by secreting exosomes loaded with miR-199a-5p that target BIP to inhibit endoplasmic reticulum stress at the very early reperfusion stages. *FASEB J* 33: 5440-5456, 2019.
13. Zhang W, Zhou B, Yang X, Zhao J, Hu J, Ding Y, Zhan S, Yang Y, Chen J, Zhang F, *et al*: Exosomal circEZH2_005, an intestinal injury biomarker, alleviates intestinal ischemia/reperfusion injury by mediating Gprc5a signaling. *Nat Commun* 14: 5437-5453, 2023.
14. Zhu G, Pei L, Lin F, Yin H, Li X, He W, Liu N and Gou X: Exosomes from human-bone-marrow-derived mesenchymal stem cells protect against renal ischemia/reperfusion injury via transferring miR-199a-3p. *J Cell Physiol* 234: 23736-23749, 2019.
15. Herman M, Randall GW, Spiegel JL, Maldonado DJ and Simoes S: Endo-lysosomal dysfunction in neurodegenerative diseases: Opinion on current progress and future direction in the use of exosomes as biomarkers. *Philos Trans R Soc Lond B Biol Sci* 379: 20220387, 2024.
16. Ma Y, Brocchini S and Williams GR: Extracellular Vesicle-embedded materials. *J Control Release* 361: 280-296, 2023.
17. Canney M, Clark EG and Hiremath S: Biomarkers in acute kidney injury: On the cusp of a new era? *J Clin Invest* 133: e171431, 2023.
18. Cao JY, Wang B, Tang TT, Wen Y, Li ZL, Feng ST, Wu M, Liu D, Yin D, Ma KL, *et al*: Exosomal miR-125b-5p deriving from mesenchymal stem cells promotes tubular repair by suppression of p53 in ischemic acute kidney injury. *Theranostics* 11: 5248-5266, 2021.
19. Wu YL, Li HF, Chen HH and Lin H: MicroRNAs as biomarkers and therapeutic targets in Inflammation- and Ischemia-Reperfusion-related acute renal injury. *Int J Mol Sci* 21: 6738, 2020.
20. Uccelli A, Moretta L and Pistoia V: Mesenchymal stem cells in health and disease. *Nat Rev Immunol* 8: 726-736, 2008.
21. Li X, Li C, Zhang L, Wu M, Cao K, Jiang F, Chen D, Li N and Li W: The significance of exosomes in the development and treatment of hepatocellular carcinoma. *Mol Cancer* 19: 1, 2020.
22. Vicencio JM, Yellon DM, Sivaraman V, Das D, Boi-Doku C, Arjun S, Zheng Y, Riquelme JA, Kearney J, Sharma V, *et al*: Plasma exosomes protect the myocardium from ischemia-reperfusion injury. *J Am Coll Cardiol* 65: 1525-1536, 2015.
23. Damania A, Jaiman D, Teotia AK and Kumar A: Mesenchymal stromal Cell-derived Exosome-rich fractionated secretome confers a hepatoprotective effect in liver injury. *Stem Cell Res Ther* 9: 31, 2018.
24. Huang Y and Yang L: Mesenchymal stem cells and extracellular vesicles in therapy against kidney diseases. *Stem Cell Res Ther* 12: 219-230, 2021.
25. Gao F, Zuo B, Wang Y, Li S, Yang J and Sun D: Protective function of exosomes from adipose tissue-derived mesenchymal stem cells in acute kidney injury through SIRT1 pathway. *Life Sci* 255: 117719, 2020.
26. Elahi FM, Farwell DG, Nolte JA and Anderson JD: Preclinical translation of exosomes derived from mesenchymal stem/stromal cells. *Stem Cells* 38: 15-21, 2020.
27. Yu Y, Chen M, Guo Q, Shen L, Liu X, Pan J, Zhang Y, Xu T, Zhang D and Wei G: Human umbilical cord mesenchymal stem cell exosome-derived miR-874-3p targeting RIPK1/PGAM5 attenuates kidney tubular epithelial cell damage. *Cell Mol Biol Lett* 28: 120, 2023.
28. Zhang W, Zhang J and Huang H: Exosomes from adipose-derived stem cells inhibit inflammation and oxidative stress in LPS-acute kidney injury. *Exp Cell Res* 420: 113332, 2022.
29. Zhou Y, Xu H, Xu W, Wang B, Wu H, Tao Y, Zhang B, Wang M, Mao F, Yan Y, *et al*: Exosomes released by human umbilical cord mesenchymal stem cells protect against cisplatin-induced renal oxidative stress and apoptosis in vivo and in vitro. *Stem Cell Res Ther* 4: 34, 2013.
30. Xing Z, Zhao C, Liu H and Fan Y: endothelial progenitor Cell-derived extracellular vesicles: A novel candidate for regenerative medicine and disease treatment. *Adv Healthc Mater* 9: e2000255, 2020.
31. Liu W, Hu C, Zhang B, Li M, Deng F and Zhao S: Exosomal microRNA-342-5p secreted from adipose-derived mesenchymal stem cells mitigates acute kidney injury in sepsis mice by inhibiting TLR9. *Biol Proced Online* 25: 10, 2023.
32. Li W, Wang W, He X, Liao Z, Aierken A, Hua J, Wang Y, Lu D and Zhang S: Rapid recovery of male cats with postrenal acute kidney injury by treating with allogeneic adipose mesenchymal stem cell-derived extracellular vesicles. *Stem Cell Res Ther* 13: 379, 2022.
33. Li X, Liao J, Su X, Li W, Bi Z, Wang J, Su Q, Huang H, Wei Y, Gao Y, *et al*: Human urine-derived stem cells protect against renal ischemia/reperfusion injury in a rat model via exosomal miR-146a-5p which targets IRAK1. *Theranostics* 10: 9561-9578, 2020.
34. Zhang Y, Wang J, Yang B, Qiao R, Li A, Guo H, Ding J, Li H, Ye H, Wu D, *et al*: Transfer of MicroRNA-216a-5p from exosomes secreted by human Urine-derived stem cells reduces renal Ischemia/reperfusion injury. *Front Cell Dev Biol* 8: 610587, 2020.
35. Grange C, Papadimitriou E, Dimuccio V, Pastorino C, Molina J, O'Kelly R, Niedernhofer LJ, Robbins PD, Camussi G and Bussolati B: Urinary extracellular vesicles carrying klotho improve the recovery of renal function in an acute tubular injury model. *Mol Ther* 28: 490-502, 2020.
36. Sun Z, Wu J, Bi Q and Wang W: Exosomal lncRNA TUG1 derived from human urine-derived stem cells attenuates renal ischemia/reperfusion injury by interacting with SRSF1 to regulate ASCL4-mediated ferroptosis. *Stem Cell Res Ther* 13: 297, 2022.
37. Thapa K, Singh TG and Kaur A: Targeting ferroptosis in ischemia/reperfusion renal injury. *Naunyn Schmiedeberg Arch Pharmacol* 395: 1331-1341, 2022.
38. Zhou Y, Que KT, Zhang Z, Yi ZJ, Zhao PX, You Y, Gong JP and Liu ZJ: Iron overloaded polarizes macrophage to proinflammation phenotype through ROS/acetyl-p53 pathway. *Cancer Med* 7: 4012-4022, 2018.
39. Wallach D, Kang TB and Kovalenko A: Concepts of tissue injury and cell death in inflammation: A historical perspective. *Nat Rev Immunol* 14: 51-59, 2014.
40. Liu L, Ye Y, Lin R, Liu T, Wang S, Feng Z, Wang X, Cao H, Chen X, Miao J, *et al*: Ferroptosis: A promising candidate for exosome-mediated regulation in different diseases. *Cell Commun Signal* 22: 6, 2024.
41. Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, Patel DN, Bauer AJ, Cantley AM, Yang WS, *et al*: Ferroptosis: An iron-dependent form of nonapoptotic cell death. *Cell* 149: 1060-1072, 2012.
42. Tsvetkov P, Coy S, Petrova B, Dreishpoon M, Verma A, Abdusamad M, Rossen J, Joesch-Cohen L, Humeidi R, Spangler RD, *et al*: Copper induces cell death by targeting lipoylated TCA cycle proteins. *Science* 375: 1254-1261, 2022.
43. Wu P, Tang Y, Jin C, Wang M, Li L, Liu Z, Shi H, Sun Z, Hou X, Chen W, *et al*: Neutrophil membrane engineered HuMSC sEVs alleviate cisplatin-induced AKI by enhancing cellular uptake and targeting. *J Nanobiotechnology* 20: 353, 2022.

44. Shi H, Xu X, Zhang B, Xu J, Pan Z, Gong A, Zhang X, Li R, Sun Y, Yan Y, *et al*: 3,3'-Diindolylmethane stimulates exosomal Wnt11 autocrine signaling in human umbilical cord mesenchymal stem cells to enhance wound healing. *Theranostics* 7: 1674-1688, 2017.
45. Ma M, Luo Q, Fan L, Li W, Li Q, Meng Y, Yun C, Wu H, Lu Y, Cui S, *et al*: The urinary exosomes derived from premature infants attenuate cisplatin-induced acute kidney injury in mice via microRNA-30a-5p/mitogen-activated protein kinase 8 (MAPK8). *Bioengineered* 13: 1650-1665, 2022.
46. Awdishu L, Le A, Amato J, Jani V, Bal S, Mills RH, Carrillo-Terrazas M, Gonzalez DJ, Tolwani A, Acharya A, *et al*: Urinary exosomes identify inflammatory pathways in vancomycin associated acute kidney injury. *Int J Mol Sci* 22: 2784, 2021.
47. Vinas JL, Burger D, Zimpelmann J, Haneef R, Knoll W, Campbell P, Gutsol A, Carter A, Allan DS and Burns KD: Transfer of microRNA-486-5p from human endothelial colony forming cell-derived exosomes reduces ischemic kidney injury. *Kidney Int* 90: 1238-1250, 2016.
48. Burger D, Vinas JL, Akbari S, Dehak H, Knoll W, Gutsol A, Carter A, Touyz RM, Allan DS and Burns KD: Human endothelial colony-forming cells protect against acute kidney injury: Role of exosomes. *Am J Pathol* 185: 2309-2323, 2015.
49. Zhang Y, Huang H, Liu W, Liu S, Wang XY, Diao ZL, Zhang AH, Guo W, Han X, Dong X and Katilov O: Endothelial progenitor cells-derived exosomal microRNA-21-5p alleviates sepsis-induced acute kidney injury by inhibiting RUNX1 expression. *Cell Death Dis* 12: 335, 2021.
50. Keung C, Nguyen TC, Lim R, Gerstenmaier A, Sievert W and Moore GT: Local fistula injection of allogeneic human amnion epithelial cells is safe and well tolerated in patients with refractory complex perianal Crohn's disease: A phase I open label study with long-term follow up. *EBioMedicine* 98: 1048799, 2023.
51. Chi D, Chen Y, Xiang C, Yao W, Wang H, Zheng X, Xu D, Li N, Xie M, Wang S, *et al*: Human Amnion epithelial cells and their derived exosomes alleviate Sepsis-associated acute kidney injury via mitigating endothelial dysfunction. *Front Med (Lausanne)* 9: 829606, 2022.
52. Kang X, Chen Y, Xin X, Liu M, Ma Y, Ren Y, Ji J, Yu Q, Qu L, Wang S, *et al*: Human amniotic epithelial cells and their derived exosomes protect against Cisplatin-induced acute kidney injury without compromising its antitumor activity in mice. *Front Cell Dev Biol* 9: 752053, 2021.
53. Lv LL, Feng Y, Wu M, Wang B, Li ZL, Zhong X, Wu WJ, Chen J, Ni HF, Tang TT, *et al*: Exosomal miRNA-19b-3p of tubular epithelial cells promotes M1 macrophage activation in kidney injury. *Cell Death Differ* 27: 210-226, 2020.
54. Guo C, Cui Y, Jiao M, Yao J, Zhao J, Tian Y, Dong J and Liao L: Crosstalk between proximal tubular epithelial cells and other interstitial cells in tubulointerstitial fibrosis after renal injury. *Front Endocrinol (Lausanne)* 14: 1256375, 2023.
55. Chen Y, Zhang C, Du Y, Yang X, Liu M, Yang W, Lei G and Wang G: Exosomal transfer of microRNA-590-3p between renal tubular epithelial cells after renal Ischemia-reperfusion injury regulates autophagy by targeting TRAF6. *Chin Med J (Engl)* 135: 2467-2477, 2022.
56. Ganesh A and Testai FD: Remote ischemic conditioning for acute ischemic stroke: Does stroke etiology matter? *Stroke* 55: 880-882, 2024.
57. Han R, Yang X, Ji X and Zhou B: Remote ischemic preconditioning prevents high-altitude cerebral edema by enhancing glucose metabolic reprogramming. *CNS Neurosci Ther* 30: e70026, 2024.
58. Torregroza C, Gnaegy L, Raupach A, Stroethoff M, Feige K, Heinen A, Hollmann MW and Huhn R: Influence of hyperglycemia and diabetes on cardioprotection by humoral factors released after remote ischemic preconditioning (RIPC). *Int J Mol Sci* 22: 8880, 2021.
59. Mukai A, Suehiro K, Kimura A, Fujimoto Y, Funao T, Mori T and Nishikawa K: Protective effects of remote ischemic preconditioning against spinal cord ischemia-reperfusion injury in rats. *J Thorac Cardiovasc Surg* 163: e137-e156, 2022.
60. Wang Y, Liu X, Wang B, Sun H, Ren Y and Zhang H: Compounding engineered mesenchymal stem cell-derived exosomes: A potential rescue strategy for retinal degeneration. *Biomed Pharmacother* 173: 116424, 2024.
61. Wang Y, Huo Y, Zhao C, Liu H, Shao Y, Zhu C, An L, Chen X and Chen Z: Engineered exosomes with enhanced stability and delivery efficiency for glioblastoma therapy. *J Control Release* 368: 170-183, 2024.
62. Donoso-Quezada J, Ayala-Mar S and Gonzalez-Valdez J: State-of-the-art exosome loading and functionalization techniques for enhanced therapeutics: A review. *Crit Rev Biotechnol* 40: 804-820, 2020.
63. Piffoux M, Volatron J, Cherukula K, Aubertin K, Wilhelm C, Silva AKA and Gazeau F: Engineering and loading therapeutic extracellular vesicles for clinical translation: A data reporting frame for comparability. *Adv Drug Deliv Rev* 178: 113972, 2021.
64. Mousavi SM, Hashemi SA, Gholami A, Kalashgrani MY, Vijayakameswara Rao N, Omidifar N, Hsiao WW, Lai CW and Chiang WH: Plasma-enabled smart nanoexosome platform as emerging immunopathogenesis for clinical viral infection. *Pharmaceutics* 14: 1054, 2022.
65. Tran PHL, Wang T, Yin W, Tran TTD, Nguyen TNG, Lee BJ and Duan W: Aspirin-loaded nanoexosomes as cancer therapeutics. *Int J Pharm* 572: 118786, 2019.
66. Ji P, Yang Z, Li H, Wei M, Yang G, Xing H and Li Q: Smart exosomes with lymph node homing and immune-amplifying capacities for enhanced immunotherapy of metastatic breast cancer. *Mol Ther Nucleic Acids* 26: 987-996, 2021.
67. Latifkar A, Hur YH, Sanchez JC, Cerione RA and Antonyak MA: New insights into extracellular vesicle biogenesis and function. *J Cell Sci* 132: jcs222406, 2019.
68. Guo M, Ge X, Wang C, Yin Z, Jia Z, Hu T, Li M, Wang D, Han Z, Wang L, *et al*: Intranasal delivery of Gene-edited microglial exosomes improves neurological outcomes after intracerebral hemorrhage by regulating neuroinflammation. *Brain Sci* 13: 639, 2023.
69. Hyun J, Eom J, Im J, Kim YJ, Seo I, Kim SW, Im GB, Kim YH, Lee DH, Park HS, *et al*: Fibroblast function recovery through rejuvenation effect of nanovesicles extracted from human adipose-derived stem cells irradiated with red light. *J Control Release* 368: 453-465, 2024.
70. Xiong J, Liu Z, Jia L, Sun Y, Guo R, Xi T, Li Z, Wu M, Jiang H and Li Y: Bioinspired engineering ADSC nanovesicles thermosensitive hydrogel enhance autophagy of dermal papilla cells for androgenetic alopecia treatment. *Bioact Mater* 36: 112-125, 2024.
71. Tan X, Zhang J, Heng Y, Chen L, Wang Y, Wu S, Liu X, Xu B, Yu Z and Gu R: Locally delivered hydrogels with controlled release of nanoscale exosomes promote cardiac repair after myocardial infarction. *J Control Release* 368: 303-317, 2024.
72. Chen Z, Hu F, Xiang J, Zhou X, Wu B, Fan B, Tang H, Liu B and Chen L: Mesoporous microneedles enabled localized controllable delivery of stimulator of interferon gene agonist nanoexosomes for FLASH radioimmunotherapy against breast cancer. *ACS Appl Mater Interfaces* 16: 58180-58190, 2024.
73. Tan A, Rajadas J and Seifalian AM: Exosomes as nanotheranostic delivery platforms for gene therapy. *Adv Drug Deliv Rev* 65: 357-367, 2013.
74. Zhao Y, Pu M, Wang Y, Yu L, Song X and He Z: Application of nanotechnology in acute kidney injury: From diagnosis to therapeutic implications. *J Control Release* 336: 233-251, 2021.
75. Sun T, Jiang D, Rosenkrans ZT, Ehlerding EB, Ni D, Qi C, Kuttyreff CJ, Barnhart TE, Engle JW, Huang P and Cai W: A Melanin-based natural antioxidant defense nanosystem for theranostic application in acute kidney injury. *Adv Funct Mater* 29: 10.1002/adfm.201904833, 2019.
76. Mi L, Wang P, Yan J, Qian J, Lu J, Yu J, Wang Y, Liu H, Zhu M, Wan Y and Liu S: A novel photoelectrochemical immunosensor by integration of nanobody and TiO₂ nanotubes for sensitive detection of serum cystatin C. *Anal Chim Acta* 902: 107-114, 2016.
77. Rubio-Navarro A, Carril M, Padro D, Guerrero-Hue M, Tarin C, Samaniego R, Cannata P, Cano A, Villalobos JM, Sevillano AM, *et al*: CD163-macrophages are involved in Rhabdomyolysis-induced kidney injury and may be detected by MRI with targeted Gold-coated iron oxide nanoparticles. *Theranostics* 6: 896-914, 2016.
78. Anwar M, Muhammad F, Akhtar B, Ur Rehman S and Saleemi MK: Nephroprotective effects of curcumin loaded chitosan nanoparticles in cypermethrin induced renal toxicity in rabbits. *Environ Sci Pollut Res Int* 27: 14771-14779, 2020.
79. Yu H, Jin F, Liu D, Shu G, Wang X, Qi J, Sun M, Yang P, Jiang S, Ying X and Du Y: ROS-responsive nano-drug delivery system combining mitochondria-targeting ceria nanoparticles with atorvastatin for acute kidney injury. *Theranostics* 10: 2342-2357, 2020.

80. Qin Y, Rouatbi N, Wang JT, Baker R, Spicer J, Walters AA and Al-Jamal KT: Plasmid DNA ionisable lipid nanoparticles as non-inert carriers and potent immune activators for cancer immunotherapy. *J Control Release* 369: 251-265, 2024.
81. Koo J, Lim C and Oh KT: Recent advances in intranasal administration for Brain-targeting delivery: A comprehensive review of Lipid-based nanoparticles and Stimuli-responsive gel formulations. *Int J Nanomedicine* 19: 1767-1807, 2024.
82. Wang L, Wei X, He X, Xiao S, Shi Q, Chen P, Lee J, Guo X, Liu H and Fan Y: Osteoinductive dental pulp stem Cell-derived extracellular Vesicle-loaded multifunctional hydrogel for bone regeneration. *ACS Nano* 18: 8777-8797, 2024.
83. Peng J, Yang T, Chen S, Deng N, Luo X, Liao R and Su B: Utilization of hydrogels in mesenchymal stem cell-based therapy for kidney diseases. *Tissue Eng Part B Rev* 30: 315-326, 2024.
84. Han DS, Erickson C, Hansen KC, Kirkbride-Romeo L, He Z, Rodell CB and Soranno DE: Mesenchymal stem cells delivered locally to Ischemia-reperfused kidneys via injectable hyaluronic acid hydrogels decrease extracellular matrix remodeling 1 month after injury in male mice. *Cells* 12: 1771, 2023.
85. Wang H, Shang Y, Chen X, Wang Z, Zhu D, Liu Y, Zhang C, Chen P, Wu J, Wu L, *et al*: Delivery of MSCs with a hybrid β -Sheet peptide hydrogel consisting IGF-1C domain and D-Form peptide for acute kidney injury therapy. *Int J Nanomedicine* 15: 4311-4324, 2020.
86. Xue HY and Wong HL: Targeting megalin to enhance delivery of anti-clusterin small-interfering RNA nanomedicine to chemo-treated breast cancer. *Eur J Pharm Biopharm* 81: 24-32, 2012.
87. Oroojalian F, Rezayan AH, Mehrnejad F, Nia AH, Shier WT, Abnous K and Ramezani M: Efficient megalin targeted delivery to renal proximal tubular cells mediated by modified-polymyxin B-polyethylenimine based nano-gene-carriers. *Mater Sci Eng C Mater Biol Appl* 79: 770-782, 2017.
88. Oroojalian F, Rezayan AH, Shier WT, Abnous K and Ramezani M: Megalin-targeted enhanced transfection efficiency in cultured human HK-2 renal tubular proximal cells using aminoglycoside-carboxyalkyl-polyethylenimine-containing nanoplexes. *Int J Pharm* 523: 102-120, 2017.



Copyright © 2025 Zhang et al. This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.